Terms: = Ovarian cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Clinical Outcome
10 results:
1. PTEN Deficiency in Tubo-ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with ccne1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract] [Full Text] [Related]
2. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
[TBL] [Abstract] [Full Text] [Related]
3. clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse.
Hollis RL; Carmichael J; Meynert AM; Churchman M; Hallas-Potts A; Rye T; MacKean M; Nussey F; Semple CA; Herrington CS; Gourley C
Am J Obstet Gynecol; 2019 Sep; 221(3):245.e1-245.e15. PubMed ID: 31055034
[TBL] [Abstract] [Full Text] [Related]
4. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract] [Full Text] [Related]
5. A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.
Vargas HA; Veeraraghavan H; Micco M; Nougaret S; Lakhman Y; Meier AA; Sosa R; Soslow RA; Levine DA; Weigelt B; Aghajanian C; Hricak H; Deasy J; Snyder A; Sala E
Eur Radiol; 2017 Sep; 27(9):3991-4001. PubMed ID: 28289945
[TBL] [Abstract] [Full Text] [Related]
6. ccne1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract] [Full Text] [Related]
7. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous ovarian cancer and Sensitivity to PI3K Inhibition.
Davis SJ; Sheppard KE; Anglesio MS; George J; Traficante N; Fereday S; Intermaggio MP; Menon U; Gentry-Maharaj A; Lubinski J; Gronwald J; Pearce CL; Pike MC; Wu A; Kommoss S; Pfisterer J; du Bois A; Hilpert F; Ramus SJ; Bowtell DD; Huntsman DG; Pearson RB; Simpson KJ; Campbell IG; Gorringe KL
Mol Cancer Ther; 2015 Jun; 14(6):1495-503. PubMed ID: 25852062
[TBL] [Abstract] [Full Text] [Related]
8. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.
Topp MD; Hartley L; Cook M; Heong V; Boehm E; McShane L; Pyman J; McNally O; Ananda S; Harrell M; Etemadmoghadam D; Galletta L; Alsop K; Mitchell G; Fox SB; Kerr JB; Hutt KJ; Kaufmann SH; Australian Ovarian Cancer Study ; Swisher EM; Bowtell DD; Wakefield MJ; Scott CL
Mol Oncol; 2014 May; 8(3):656-68. PubMed ID: 24560445
[TBL] [Abstract] [Full Text] [Related]
9. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.
Milea A; George SH; Matevski D; Jiang H; Madunic M; Berman HK; Gauthier ML; Gallie B; Shaw PA
Mod Pathol; 2014 Jul; 27(7):991-1001. PubMed ID: 24336157
[TBL] [Abstract] [Full Text] [Related]
10. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
Etemadmoghadam D; deFazio A; Beroukhim R; Mermel C; George J; Getz G; Tothill R; Okamoto A; Raeder MB; Harnett P; Lade S; Akslen LA; Tinker AV; Locandro B; Alsop K; Chiew YE; Traficante N; Fereday S; Johnson D; Fox S; Sellers W; Urashima M; Salvesen HB; Meyerson M; Bowtell D;
Clin Cancer Res; 2009 Feb; 15(4):1417-27. PubMed ID: 19193619
[TBL] [Abstract] [Full Text] [Related]
